Chair
Member
Audit Committee Position

Kurt H. Kruger

Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.

Chair

Richard A. David, M.D. FACS, MMM

Dr. Richard David serves as Chief Medical Officer for Skyline Urology, the largest Urology group in Los Angeles. He also serves as medical director for Skyline’s Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Associate Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. He serves on the Attending Staff in Surgery/Urology at Harbor UCLA Medical Center and Olive View UCLA Medical Center. He is certified by the American Board of Urology. His clinical and research interests include minimally invasive endoscopic treatment for urologic diseases, sexual function and prosthetics, and advanced prostate cancer. He has published extensively and presented at many international conferences in this area. He has received the “Super Doctor” designation 13 times. Dr. David serves as Chief of Surgery at Motion Picture and Television Hospital (MPTVH) in Woodland Hills, CA. In addition to MPTHV, Dr. David serves on staff at Providence St. Joseph Medical Center, Providence Tarzana Medical Center, Valley Presbyterian Hospital, Northridge Hospital Medical Center, Encino Hospital, Sherman Oaks Hospital, Harbor UCLA Medical Center and Olive View UCLA Medical Center. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Masters Degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons, a member of the American Urological Association, the American Medical Association, and the California Urologic Association. He is also a member in the American Association of Clinical Urologists, American Lithotripsy Society, Society of Laparoendoscopic Surgeons and Society of Urologic Prosthetic Surgeons.

Member

Matthew Korenberg

Mr. Korenberg has served as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, since January 2018 and before that as Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.

Member

Audit Committee Charter

Download
Compensation Committee Position

Richard A. David, M.D. FACS, MMM

Dr. Richard David serves as Chief Medical Officer for Skyline Urology, the largest Urology group in Los Angeles. He also serves as medical director for Skyline’s Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Associate Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. He serves on the Attending Staff in Surgery/Urology at Harbor UCLA Medical Center and Olive View UCLA Medical Center. He is certified by the American Board of Urology. His clinical and research interests include minimally invasive endoscopic treatment for urologic diseases, sexual function and prosthetics, and advanced prostate cancer. He has published extensively and presented at many international conferences in this area. He has received the “Super Doctor” designation 13 times. Dr. David serves as Chief of Surgery at Motion Picture and Television Hospital (MPTVH) in Woodland Hills, CA. In addition to MPTHV, Dr. David serves on staff at Providence St. Joseph Medical Center, Providence Tarzana Medical Center, Valley Presbyterian Hospital, Northridge Hospital Medical Center, Encino Hospital, Sherman Oaks Hospital, Harbor UCLA Medical Center and Olive View UCLA Medical Center. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Masters Degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons, a member of the American Urological Association, the American Medical Association, and the California Urologic Association. He is also a member in the American Association of Clinical Urologists, American Lithotripsy Society, Society of Laparoendoscopic Surgeons and Society of Urologic Prosthetic Surgeons.

Chair

Matthew Korenberg

Mr. Korenberg has served as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, since January 2018 and before that as Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.

Member

Kurt H. Kruger

Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Richard A. David, M.D. FACS, MMM

Dr. Richard David serves as Chief Medical Officer for Skyline Urology, the largest Urology group in Los Angeles. He also serves as medical director for Skyline’s Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Associate Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. He serves on the Attending Staff in Surgery/Urology at Harbor UCLA Medical Center and Olive View UCLA Medical Center. He is certified by the American Board of Urology. His clinical and research interests include minimally invasive endoscopic treatment for urologic diseases, sexual function and prosthetics, and advanced prostate cancer. He has published extensively and presented at many international conferences in this area. He has received the “Super Doctor” designation 13 times. Dr. David serves as Chief of Surgery at Motion Picture and Television Hospital (MPTVH) in Woodland Hills, CA. In addition to MPTHV, Dr. David serves on staff at Providence St. Joseph Medical Center, Providence Tarzana Medical Center, Valley Presbyterian Hospital, Northridge Hospital Medical Center, Encino Hospital, Sherman Oaks Hospital, Harbor UCLA Medical Center and Olive View UCLA Medical Center. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Masters Degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons, a member of the American Urological Association, the American Medical Association, and the California Urologic Association. He is also a member in the American Association of Clinical Urologists, American Lithotripsy Society, Society of Laparoendoscopic Surgeons and Society of Urologic Prosthetic Surgeons.

Chair

Kurt H. Kruger

Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.

Member

Nominating and Corporate Governance Committee Charter

Download

Kurt H. Kruger

Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.

Richard A. David, M.D. FACS, MMM

Dr. Richard David serves as Chief Medical Officer for Skyline Urology, the largest Urology group in Los Angeles. He also serves as medical director for Skyline’s Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Associate Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. He serves on the Attending Staff in Surgery/Urology at Harbor UCLA Medical Center and Olive View UCLA Medical Center. He is certified by the American Board of Urology. His clinical and research interests include minimally invasive endoscopic treatment for urologic diseases, sexual function and prosthetics, and advanced prostate cancer. He has published extensively and presented at many international conferences in this area. He has received the “Super Doctor” designation 13 times. Dr. David serves as Chief of Surgery at Motion Picture and Television Hospital (MPTVH) in Woodland Hills, CA. In addition to MPTHV, Dr. David serves on staff at Providence St. Joseph Medical Center, Providence Tarzana Medical Center, Valley Presbyterian Hospital, Northridge Hospital Medical Center, Encino Hospital, Sherman Oaks Hospital, Harbor UCLA Medical Center and Olive View UCLA Medical Center. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Masters Degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons, a member of the American Urological Association, the American Medical Association, and the California Urologic Association. He is also a member in the American Association of Clinical Urologists, American Lithotripsy Society, Society of Laparoendoscopic Surgeons and Society of Urologic Prosthetic Surgeons.

Matthew Korenberg

Mr. Korenberg has served as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, since January 2018 and before that as Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.

Richard A. David, M.D. FACS, MMM

Dr. Richard David serves as Chief Medical Officer for Skyline Urology, the largest Urology group in Los Angeles. He also serves as medical director for Skyline’s Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Associate Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. He serves on the Attending Staff in Surgery/Urology at Harbor UCLA Medical Center and Olive View UCLA Medical Center. He is certified by the American Board of Urology. His clinical and research interests include minimally invasive endoscopic treatment for urologic diseases, sexual function and prosthetics, and advanced prostate cancer. He has published extensively and presented at many international conferences in this area. He has received the “Super Doctor” designation 13 times. Dr. David serves as Chief of Surgery at Motion Picture and Television Hospital (MPTVH) in Woodland Hills, CA. In addition to MPTHV, Dr. David serves on staff at Providence St. Joseph Medical Center, Providence Tarzana Medical Center, Valley Presbyterian Hospital, Northridge Hospital Medical Center, Encino Hospital, Sherman Oaks Hospital, Harbor UCLA Medical Center and Olive View UCLA Medical Center. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Masters Degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons, a member of the American Urological Association, the American Medical Association, and the California Urologic Association. He is also a member in the American Association of Clinical Urologists, American Lithotripsy Society, Society of Laparoendoscopic Surgeons and Society of Urologic Prosthetic Surgeons.

Matthew Korenberg

Mr. Korenberg has served as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, since January 2018 and before that as Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.

Kurt H. Kruger

Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.

Richard A. David, M.D. FACS, MMM

Dr. Richard David serves as Chief Medical Officer for Skyline Urology, the largest Urology group in Los Angeles. He also serves as medical director for Skyline’s Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Associate Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. He serves on the Attending Staff in Surgery/Urology at Harbor UCLA Medical Center and Olive View UCLA Medical Center. He is certified by the American Board of Urology. His clinical and research interests include minimally invasive endoscopic treatment for urologic diseases, sexual function and prosthetics, and advanced prostate cancer. He has published extensively and presented at many international conferences in this area. He has received the “Super Doctor” designation 13 times. Dr. David serves as Chief of Surgery at Motion Picture and Television Hospital (MPTVH) in Woodland Hills, CA. In addition to MPTHV, Dr. David serves on staff at Providence St. Joseph Medical Center, Providence Tarzana Medical Center, Valley Presbyterian Hospital, Northridge Hospital Medical Center, Encino Hospital, Sherman Oaks Hospital, Harbor UCLA Medical Center and Olive View UCLA Medical Center. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Masters Degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons, a member of the American Urological Association, the American Medical Association, and the California Urologic Association. He is also a member in the American Association of Clinical Urologists, American Lithotripsy Society, Society of Laparoendoscopic Surgeons and Society of Urologic Prosthetic Surgeons.

Kurt H. Kruger

Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.